Compare Equinix Inc (EQIX) vs 10X Genomics Inc (TXG) Price & Performance

Equinix (EQIX) trades at $1,005.31, down 1.78% today, with a bearish technical signal despite strong analyst support. The company reported mixed Q1 2026 earnings with a slight miss on EPS expectations but maintains robust revenue growth and profitability. Recent partnerships with Cisco and NVIDIA position EQIX well for AI infrastructure demand, though high valuation ratios and negative cash flow trends present challenges.

The outlook remains cautiously optimistic with 74.5% analyst buy ratings and a $1,110 consensus price target suggesting 10% upside. Key risks include elevated debt levels, aggressive capital expenditure, and competitive pressures in the data center REIT sector. The stock offers exposure to digital infrastructure growth but requires monitoring of cash flow sustainability.

10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.

While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.